Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAB2 | O43741 | 1/20 | 0.87 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.87 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.87 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.87 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.87 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.87 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.87 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA4 | P22748 | 2/20 | 0.42 |
| ▸ | CA6 | P23280 | 2/20 | 0.42 |
| ▸ | CA5A | P35218 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL716606 | 0.93 | PRKAB2 (1.00) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL29611296 | 0.93 | PRKAB2 (1.00) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL19236034 | 0.93 | PRKAB2 (1.00) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL10001662 | 0.93 | PRKAB2 (1.00) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL20880463 | 0.85 | PRKAB2 (0.85) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL10001663 | 0.85 | PRKAB2 (0.85) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL14922196 | 0.83 | PRKAB2 (0.83) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL31685604 | 0.83 | PRKAB2 (0.71) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL20663726 | 0.83 | PRKAB2 (0.81) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL20663730 | 0.82 | PRKAB2 (0.81) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10596144-B2 | Treating or preventing nephrogenic diabetes insipidus | EMORY UNIVERSITY (US) | 2020-03-24 | — | — | US | claimed |
| US-20180092876-A1 | Treating or Preventing Nephrogenic Diabetes Insipidus | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-04-05 | — | — | US | claimed |
| US-9827222-B2 | Treating or preventing nephrogenic diabetes insipidus | EMORY UNIVERSITY (US) | 2017-11-28 | — | — | US | claimed |
| US-20230364039-A1 | Methods of Managing Side Effects of a Vasopressin Receptor Antagonist Therapy | UNIV EMORY (US) | 2023-11-16 | — | — | US | disclosed |
| US-20220031639-A1 | SUBSTITUTED CYCLOALKANES FOR MANAGING NEPHROGENIC DIABETES INSIPIDUS | NEPHRODI THERAPEUTICS, INC. | 2022-02-03 | — | — | US | disclosed |
| US-11179354-B2 | Substituted cycloalkanes for managing nephrogenic diabetes insipidus | NEPHRODI THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20200383940-A1 | Managing Nephrogenic Diabetes Insipidus | EMORY UNIVERSITY | 2020-12-10 | — | — | US | disclosed |
| EP-3618821-A1 | MANAGING NEPHROGENIC DIABETES INSIPIDUS | Emory University (US) | 2020-03-11 | — | — | EP | disclosed |
| WO-2018144570-A1 | MANAGING NEPHROGENIC DIABETES INSIPIDUS | EMORY UNIVERSITY (US) | 2018-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364039-A1 | Methods of Managing Side Effects of a Vasopressin Receptor Antagonist Therapy | AVPR2, AVPR1A, AVPR1B | PRKAB2 29/4885PRKAG1 12/4885PRKAA2 25/4885 |
| US-20220031639-A1 | SUBSTITUTED CYCLOALKANES FOR MANAGING NEPHROGENIC DIABETES INSIPIDUS | SLC5A2, SLC5A1, IAPP | PRKAB2 3417/4885PRKAG1 3436/4885PRKAA2 2741/4885 |
| US-20200383940-A1 | Managing Nephrogenic Diabetes Insipidus | SLC5A2, SLC5A1, IAPP | PRKAB2 3120/4885PRKAG1 3042/4885PRKAA2 2819/4885 |
| US-11179354-B2 | Substituted cycloalkanes for managing nephrogenic diabetes insipidus | SLC5A2, SLC5A1, IAPP | PRKAB2 3380/4885PRKAG1 3518/4885PRKAA2 2582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.